Key Points
- Director Stephen Bloch sold 62,550 shares on March 27 at an average price of $35.94 for about $2.248 million, leaving him with 2,188,935 shares (a 2.78% reduction in his stake).
- Liquidia beat the quarter, reporting $0.15 EPS vs. $0.08 expected and $92.02M revenue (up ~3,072% year‑over‑year), but the company still shows negative ROE (‑209.33%) and net margin (‑43.53%) with analysts forecasting -1.51 EPS for the year.
- Analyst and institutional interest is strong, with recent price‑target raises (Wells Fargo to $51, Needham to $54), an average target of $43.44 and a consensus "Moderate Buy," while institutional investors own 64.54% of the shares.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 62,550 shares of the company's stock in a transaction dated Friday, March 27th. The shares were sold at an average price of $35.94, for a total transaction of $2,248,047.00. Following the sale, the director owned 2,188,935 shares in the company, valued at $78,670,323.90. This represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Liquidia Stock Up 0.6%
Shares of NASDAQ:LQDA opened at $37.68 on Friday. The company has a market cap of $3.32 billion, a price-to-earnings ratio of -45.40 and a beta of 0.45. Liquidia Corporation has a 12 month low of $11.26 and a 12 month high of $46.67. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. The company has a 50-day moving average price of $37.44 and a 200 day moving average price of $32.09.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company had revenue of $92.02 million for the quarter, compared to analysts' expectations of $87.49 million. The firm's revenue was up 3072.4% compared to the same quarter last year. As a group, equities research analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms recently weighed in on LQDA. Wells Fargo & Company increased their price target on Liquidia from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Monday, March 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Liquidia in a research report on Thursday, January 22nd. Raymond James Financial reissued a "strong-buy" rating on shares of Liquidia in a research note on Thursday, March 5th. Lifesci Capital upgraded shares of Liquidia to a "strong-buy" rating in a report on Thursday, March 5th. Finally, Needham & Company LLC lifted their price target on shares of Liquidia from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Liquidia presently has an average rating of "Moderate Buy" and an average price target of $43.44.
View Our Latest Report on LQDA
Hedge Funds Weigh In On Liquidia
Large investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new position in Liquidia in the 4th quarter valued at $3,148,000. Invesco Ltd. lifted its position in shares of Liquidia by 428.3% during the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company's stock worth $14,507,000 after purchasing an additional 341,009 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Liquidia during the fourth quarter valued at $1,214,000. nVerses Capital LLC bought a new position in shares of Liquidia in the fourth quarter worth about $335,000. Finally, Occudo Quantitative Strategies LP bought a new position in shares of Liquidia in the fourth quarter worth about $3,107,000. Hedge funds and other institutional investors own 64.54% of the company's stock.
Liquidia Company Profile
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
